Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Moody's Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Moody's Corporation trades at $463.02 (market cap $80.14B). The key difference: Moody's Corporation is far larger — about 9× Kymera Therapeutics Inc. Common Stock's market cap, and Moody's Corporation pays a 0.89% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Moody's Corporation for 133 Days on average.
| KYMR | MCO | |
|---|---|---|
Market Cap | $8.88B | $80.14B |
Volume | 1,028,790 | 829,155 |
Sector | Health | Financials |
52-Week High | $127.31 | $539.61 |
52-Week Low | $55.80 | $412.23 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $8.27B | $86.17B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MCO trades at $464.13, down 1.35% today, but maintains a bullish technical outlook with strong support at $464. Revenue grew to $7.72B in 2025 with a net income margin of 34.25%, and the company has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic moves like a minority stake in PhilRatings to bolster Asia-Pacific presence and a top RiskTech100 ranking for the fifth year.
The outlook remains positive with a consensus price target of $536.40, implying 15.6% upside, supported by robust profitability and growth initiatives. Key risks include high valuation multiples and exposure to economic cycles affecting credit demand. Analyst sentiment is predominantly bullish with 18 buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
